Cybin Inc. (CYBN) Dividend History

Cybin Inc. is a biotechnology company focused on the development of psychedelic-based therapies for mental health and neurological disorders. Established to advance psychedelic compounds through clinical research, the company aims to provide innovative treatment options for conditions such as depression, anxiety, and addiction. Cybin emphasizes its commitment to scientific rigor and the responsible development of psychedelic medicines.

Dividend History

Cybin Inc. currently does not pay dividends

Company News

Psychedelic Science 2025 Announces Select Speakers for the Leading Conference on Psychedelic Research, Policy, and Thought Leadership

Psychedelic Science 2025, a leading conference on psychedelic research, policy, and thought leadership, announces its initial lineup of speakers, including former U.S. Senator Kyrsten Sinema, former Ohio Representative Tim Ryan, and other prominent researchers, policymakers, and advocates.

GlobeNewswire Inc.
5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

The 5-HT2 agonist pipeline is robust, with over 20 pharmaceutical companies actively developing 22+ pipeline drugs. Advancements in precision medicine and personalized approaches are driving the market, enabling selective targeting of receptor subtypes and improving safety and efficacy.

GlobeNewswire Inc.

Featured Companies: ATAI HRMY MNMD RVPH
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”

Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc., a leader in novel neuropsychiatry therapeutics. Cybin's primary focus is on two lead pipeline candidates, CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder, which have shown promising results in clinical trials.

GlobeNewswire Inc.
What Makes Cybin Inc. (CYBN) a New Buy Stock

Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research
Down -17.45% in 4 Weeks, Here's Why Cybin Inc. (CYBN) Looks Ripe for a Turnaround

Cybin Inc. (CYBN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Investment Research

Dividend data last updated 06/07/2025 20:39:35 UTC